Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Reports and Publications - MedEffect Canada - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 168724
Later capture
Reports and Publications - MedEffect Canada - Canada.ca
Jan 2, 2026
hc-20260101
ID 428947
updated3 sections changed; 4 added; 5 removed
3 sections changed4 added5 removed+9 / -12 linesChange ratio: 9%
--- +++ @@ -1,4 +1,4 @@-Reports and Publications - MedEffect Canada+Reports and publications - MedEffect Canada MedEffect Canada Home Page Report an Adverse Reaction Learn About Adverse Reactions@@ -9,17 +9,15 @@ Publications that no longer appear on this Web site may be found on the Government of Canada publications site.-Fact Sheets, Brochures, Pamphlets-Guidance Documents and Guidelines+Fact sheets, brochures, pamphlets+Guidance documents Reports-Fact Sheets, Brochures, Pamphlets+Fact sheets, brochures, pamphlets 2019 Suspect a serious adverse drug reaction or medical device incident (poster) 2012 Health Product Vigilance Framework 2011-Patient Guide for Reporting Side Effects-Adverse Reaction Reporting and Health Product Safety Information - Guide for Health Professionals Insert - Adverse Reaction Reporting for Natural Health Products MedEffect TM@@ -36,9 +34,11 @@ (It's Your Health) 2008 Poster - Cough and Cold Medicine for Children-Tear Sheet - Cough and Cold Medicine for Children-Guidance Documents and Guidelines+Guidance documents 2025+Draft guidance on preparing and submitting summary reports for marketed drugs and natural health products+Consultation on the draft guidance+Draft guidance Submitting risk management plans guidance document [2025-02-24] 2024@@ -84,8 +84,6 @@ List of Opioids: Part A - Opioids subject to the prescription labelling provisions Part B - Opioids that are subject to market authorization terms and conditions-2015-Guidance Document- Submission of Risk Management Plans and Follow-up Commitments 2014 Guidance Document for Industry - Review of Drug Brand Names [2014-07-02]@@ -97,7 +95,7 @@ 2010 Guidance Document for Source Establishment - Reporting Adverse Reactions to Human Cells, Tissues and Organs [2010-05-25]-Related Links+Related links E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories Guidance document: Electronic Canadian Drug Facts Table Technical Standards Guidance Document: Submission of Pharmacogenomic Information@@ -120,5 +118,4 @@ 2006 Public opinion survey on key issues pertaining to post-market surveillance of marketed health products in Canada, final report Page details-Date modified: 2025-02-24